Legend Biotech (LEGN) Common Equity: 2019-2025
Historic Common Equity for Legend Biotech (LEGN) over the last 3 years, with Mar 2025 value amounting to $1.0 billion.
- Legend Biotech's Common Equity fell 12.57% to $1.0 billion in Q1 2025 from the same period last year, while for Mar 2025 it was $1.0 billion, marking a year-over-year decrease of 12.57%. This contributed to the annual value of $1.0 billion for FY2024, which is 16.85% down from last year.
- Legend Biotech's Common Equity amounted to $1.0 billion in Q1 2025, which was down 2.19% from $1.0 billion recorded in Q4 2024.
- Legend Biotech's Common Equity's 5-year high stood at $1.4 billion during Q2 2023, with a 5-year trough of $206,451 in Q1 2021.
- In the last 3 years, Legend Biotech's Common Equity had a median value of $1.2 billion in 2024 and averaged $1.1 billion.
- Its Common Equity has fluctuated over the past 5 years, first surged by 358,900.44% in 2022, then decreased by 17.63% in 2024.
- Over the past 5 years, Legend Biotech's Common Equity (Quarterly) stood at $765.9 million in 2021, then declined by 2.82% to $744.3 million in 2022, then skyrocketed by 68.12% to $1.3 billion in 2023, then fell by 16.85% to $1.0 billion in 2024, then decreased by 12.57% to $1.0 billion in 2025.
- Its Common Equity stands at $1.0 billion for Q1 2025, versus $1.0 billion for Q4 2024 and $1.1 billion for Q3 2024.